Form 4: VolitionRx Director Innes Amends Stock Options

Director Guy Archibald Innes amends stock options at VolitionRx, resulting in the cancellation of old options and the grant of replacement options.

Summary

• On January 29, 2025, Guy Archibald Innes, a director of VolitionRx Ltd, amended his stock options.
• The transaction involved the cancellation of old options and the grant of replacement options.
• The old options were originally granted on February 11, 2019, vested in full after 12 months, and were exercisable for five years.
• The replacement options are fully vested and expire on February 11, 2029, ten years from the original grant date.
• Both the old and replacement options have an exercise price of $3.25.
• The number of options involved in the transaction is 25,000.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The extension of the option period could be viewed slightly positively as it provides the director with more time to benefit from potential stock appreciation.

Positives

• The replacement options provide Innes with a longer exercise period, extending to February 11, 2029.

Industry Context

Stock option grants and amendments are common practices for incentivizing and retaining key personnel, such as directors, in publicly traded companies.

Comparison to Industry Standards

• Stock option plans are a standard component of executive compensation packages in the biotechnology industry, used by companies like Exact Sciences and Guardant Health to align management interests with shareholder value.
• The vesting schedules and expiration dates of these options are generally in line with industry norms, designed to incentivize long-term performance.

Stakeholder Impact

• The amendment of stock options could potentially impact shareholders by aligning the director's interests with the long-term performance of the company.

Key Dates